YIH
GALT icon

Y-Intercept (HK)’s Galectin Therapeutics GALT Stock Holding History

Y-Intercept (HK)’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-235,192
Closed -$287K – 1759
2025
Q1 		$287K Buy
+235,192
New +$330K 0.02% 921
2024
Q2 		– Sell
-11,140
Closed -$26.6K – 1558
2024
Q1 		$26.6K Buy
+11,140
New +$21.1K ﹤0.01% 1312

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.9B AUM 23.65% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Y-Intercept (HK)'s GALT Position: Q2 2025 in Review

Y-Intercept (HK) sold out of Galectin Therapeutics (GALT) in Q2 2025, closing a stake of 235,192 shares — an estimated $287K sold.

Y-Intercept (HK) first reported a position in GALT in Q1 2024 and held it in 2 quarters. The position peaked at $287K in Q1 2025. 86 funds tracked by Wall St. Rank hold GALT as of Q2 2025.

  • Y-Intercept (HK) reported no remaining Galectin Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Y-Intercept (HK) sold 235,192 Galectin Therapeutics shares in Q2 2025, an estimated $287K.
  • Y-Intercept (HK) first reported a position in Galectin Therapeutics in Q1 2024 and held it in 2 quarters.
  • Y-Intercept (HK)'s Galectin Therapeutics position peaked at $287K in Q1 2025.
  • 86 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2025.

Based on Y-Intercept (HK)'s 13F filing for Q2 2025, filed 1 Aug 2025.